United States Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP) Bernie Sanders announced in a statement that CEOs from Johnson & Johnson and Merck & Co. Inc. will be joining Bristol Myers Squibb Co. CEO Chris Boerner at a hearing related to "outrageously...
Bristol-Myers Squibb Company will acquire Boston-based biotech company Karuna Therapeutics for $14 billion, The Wall Street Journal reported on Friday.
The pharmaceutical giant based in Princeton is anticipated to make a cash payment of $330 per share for Karuna, including its experimental...
Bristol-Myers Squibb Company announced it will acquire Mirati Therapeutics Inc. for $58 per share in cash in a transaction that will amount to $4.8 billion. The deal is expected to clear the regulatory process and to be finalized by the first half of 2024.
"Mirati is a commercial stage targeted...
Bristol-Myers Squibb announced on Monday it will acquire MyoKardia Inc in an all-cash deal worth $13.1 billion, or $225 a share.
MyoKardia specializes in heart treatment and its experimental drug code-named mavacamten, which treats a chronic heart condition called hypertrophic...
The United States Federal Trade Commission (FTC) has approved the acquisition of American biotechnology firm Celgene Corp. by pharmaceutical giant Bristol-Myers Squibb Co., the buyer announced on Friday. It also noted it expects to close the transaction on November 20. The $74 billion deal was...
Bristol-Myers Squibb Co. announced on Monday that Amgen will acquire the rights to Celgene Corporation's Otezla drug in a cash deal worth $13.4 billion. Bristol-Myers previously said it would divest Otezla in an effort to secure the regulatory approval for its proposed merger with Celgene.
"This...
Bristol-Myers Squibb Co. is planning to divest its Otezla drug in order to obtain the United States Federal Trade Commission's (FTC) approval for its proposed merger with Celgene Corporation, the former announced in a press release on Monday.
Bristol-Myers' divestiture of the Otezla drug, which...
Celgene Corporation announced on Friday that its shareholders approved Bristol-Myers Squibb Co's proposed acquisition of the company in a cash and stock deal worth approximately $74 billion.
The biotechnology company noted that about 98% of the votes cast were in favor of the transaction. "On...
Novartis International AG agreed to take over IFM Tre from Bristol-Myers Squibb Co. for an undisclosed sum. In the announcement published on Monday, the Swiss pharmaceutical giant highlighted one clinical and two preclinical programs targeting the NLRP3 inflammasome complex with...
Hedge fund Starboard Value LP announced it will vote against the proposed Bristol-Myers Squibb Co. acquisition of Celgene Corp., making it the second large stakeholder to denounce the transaction.
"We are writing today as we believe that Bristol-Myers is deeply undervalued and the recent...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
